Mymetics Corp (MYMX)

[bow-tie]

In 2012 a start-up company called Biolife Science had been incorporated to develop this immunotherapy. Early-stage funding was secured from Australian and US investors in 2013, after which Biolife was taken public in December 2013 in a reverse takeover of an Australian drug development company called Imugene, whose name was retained after the merger. Around US$8m was spent on the HER-Vaxx programme prior to its becoming the 'new Imugene'.

Positive Phase I Trial Results for Pevion Biotech Ltd.'s and Bio Life Science's Breast Cancer Vaccine | BioSpace
... s and Bio Life Sciences Breast Cancer Vaccine - read this article along with other careers information, tips and advice on ... For its vaccine development, the company uses its virosome-based technology which is already validated by two registered and ... The vaccine was generally well tolerated and no vaccine-related serious or severe adverse effects were reported. The vaccine ... The trivalent vaccine was found to be safe, well tolerated and immunogenic in patients moderately over-expressing the HER-2/neu ...

https://www.biospace.com/article/releases/positive-phase-i-trial-results-for-pevion-biotech-ltd-s-and-b-bio-life-science-b-s-breast-cancer-vaccine-/